BPC-157 is a research peptide studied for its role in recovery & healing research. This page covers its mechanism of action, published research, preclinical protocols, and analytical specifications for researchers.
-20°C (lyophilized); 4°C after reconstitution, use within 28 days
Reconstitution
Add 2ml bacteriostatic water per 10mg vial. Inject slowly along vial wall, swirl gently — do not shake.
Mechanism of Action
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids, originally isolated from a sequence found in human gastric juice. Unlike many peptides with a single receptor target, BPC-157 appears to act through multiple simultaneous pathways, which has made it a subject of broad preclinical research interest.
Nitric Oxide (NO) Signaling: Research suggests BPC-157 modulates nitric oxide synthesis, influencing local blood flow and vascular tone in injured tissue. This mechanism is thought to contribute to its observed effects on wound healing in preclinical models by improving perfusion to damaged areas.
Growth Factor Upregulation: Studies indicate BPC-157 upregulates vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) expression, promoting angiogenesis (new blood vessel formation) and cellular proliferation at sites of tissue damage.
Tendon Fibroblast Activity: In tendon injury models, BPC-157 has been shown to stimulate tenocyte (tendon cell) outgrowth and collagen organization, suggesting a direct role in structural tissue repair independent of purely vascular mechanisms.
GABAergic and Dopaminergic Interaction: A distinct line of research has examined BPC-157’s interaction with central neurotransmitter systems, including GABA-B receptors and dopamine pathways, though the relevance to its peripheral healing effects remains an active area of investigation.
Research Applications
The majority of published BPC-157 research has been conducted in rodent models. Key research areas include:
Tendon and Ligament Repair: Multiple studies have examined BPC-157’s effects on Achilles tendon transection models, showing accelerated fibroblast migration and collagen deposition compared to controls.
Gastrointestinal Mucosal Healing: As a peptide derived from gastric juice, BPC-157 has been extensively studied in models of gastric ulceration, inflammatory bowel disease, and esophageal damage, consistently demonstrating cytoprotective and healing effects.
Bone and Cartilage Research: Studies in segmental bone defect and cartilage injury models have explored BPC-157’s potential role in osteoblast activity and chondrocyte function.
Organ Protection Research: A body of work from the Sikiric research group has documented BPC-157’s apparent protective effects across multiple organ systems in rodent toxicity models, including hepatic, cardiac, and renal tissue.
Neurological Research: Emerging preclinical research has examined BPC-157 in models of traumatic brain injury and peripheral nerve damage, with observed effects on nerve regeneration markers.
Key Published Research
The following publications represent primary research relevant to BPC-157. Full citations are available via PubMed. QSC does not endorse or make claims based on this research.
Sikiric et al. (2018)
“Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract” — Current Pharmaceutical Design
Comprehensive review of BPC-157’s GI mucosal protective mechanisms and cytoprotective properties across multiple GI injury models.
Gwyer et al. (2019)
“Gastric Pentadecapeptide Body Protection Compound BPC 157 and Its Role in Accelerating Musculoskeletal Soft Tissue Healing” — Cell and Tissue Research
Systematic review of BPC-157 research in tendon, ligament, and muscle injury models, summarizing proposed mechanisms and study methodologies.
Sikiric et al. (2020)
“Brain-Gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications” — Current Neuropharmacology
Examines BPC-157’s interaction with central and enteric nervous systems, including neurotransmitter pathway research.
Barbir et al. (2022)
“Pentadecapeptide BPC 157 Interactions with Dopamine Agonist and Antagonist” — Biomedicines
Investigates BPC-157’s modulation of dopaminergic activity in rodent behavioral and physiological models.
Research Protocol Reference
The following dosing information reflects parameters used in published preclinical (animal) research only. It is provided for informational context regarding published study methodology and does not constitute dosing guidance for human use.
Model / Context
Dose Range
Route
Protocol Notes
Rodent Tendon Model
10 μg/kg – 10 mg/kg
Intraperitoneal or subcutaneous
Typically daily administration over 7–21 days post-injury in published rodent studies
Rodent GI Model
10 μg/kg – 10 mg/kg
Oral or intraperitoneal
Acute or chronic protocols depending on injury model; duration varies by study design
Rodent Systemic Model
2 μg/kg – 10 mg/kg
Various routes
Highly variable across published studies; route and dose selection dependent on model and endpoint
Frequently Asked Questions
What is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a sequence found in human gastric juice and is studied in preclinical research for its apparent effects on tissue repair, gastrointestinal healing, and multi-system cytoprotection.
What does BPC-157 stand for?
BPC stands for Body Protection Compound. The 157 designation refers to its sequence position within the parent protein from which it was originally isolated in gastric juice research.
Is BPC-157 the same as TB-500?
No. BPC-157 is a 15-amino acid peptide derived from gastric juice proteins, while TB-500 is a synthetic fragment of Thymosin Beta-4, derived from thymic tissue. They have distinct sequences, receptor targets, and mechanisms, though researchers have studied them in combination as a recovery-focused stack.
How should BPC-157 be stored?
Lyophilized (freeze-dried) BPC-157 should be stored at -20°C in a sealed, moisture-free environment. After reconstitution with bacteriostatic water, the solution should be refrigerated at 4°C and used within 28 days. Avoid repeated freeze-thaw cycles.
What is the purity of QSC BPC-157?
QSC BPC-157 is verified at ≥99% purity by HPLC analysis and mass spectrometry. A Certificate of Analysis (COA) is published on the product page and independently verifiable via the Janoshik testing portal.
Research Use Only: All products sold on qsc-usa.com are intended strictly for laboratory research purposes only. They are not approved for human consumption, veterinary use, or any other application. Researchers are responsible for understanding and complying with local regulations governing research chemicals in their jurisdiction.
